| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
Norepinephrine transporter; Vesicular monoamine transporter (VMAT)
|
|---|---|
| ln Vitro |
FFN270 allows for the detection of synaptic activity in the cortex of intact neural circuits in vivo as well as the study of noradrenergic microanatomy[1].
FFN270 hydrochloride is a fluorescent substrate of the norepinephrine and vesicular monoamine transporters. Depending on pH value, FFN270 has two resolved absorption wavelengths and one excitation wavelength (ex: 320 nm or 365 nm, em: 475 nm), which can be utilized as a ratiometric fluorescence sensor. |
| ln Vivo |
FFN270 enables both an examination of noradrenergic microanatomy and an observation of synaptic activity in the cortex of intact neuronal circuits in vivo. It allows real-time monitoring of norepinephrine dynamics and vesicular transport processes in living neurons, providing a powerful tool for studying neurotransmitter release and reuptake.
|
| Enzyme Assay |
Assays using FFN270 typically involve loading the fluorescent tracer into cultured neurons or brain slices. Cells are incubated with FFN270 at appropriate concentrations (typically 1-10 microM) for 30-60 min. Fluorescence imaging is performed using confocal microscopy at excitation wavelengths of 320 nm or 365 nm and emission at 475 nm. Uptake specificity is confirmed using selective transporter inhibitors.
|
| Cell Assay |
For in vitro cellular assays, primary neuronal cultures or SH-SY5Y cells are seeded on coverslips and treated with FFN270 hydrochloride (1-10 microM) for 30-60 min at 37degC. Cells are then washed and imaged using fluorescence microscopy. Norepinephrine transporter-specific uptake is validated by co-incubation with desipramine or other selective inhibitors. Fluorescence intensity indicates transporter activity.
|
| Animal Protocol |
In vivo experiments involve stereotaxic injection of FFN270 hydrochloride into specific brain regions (e.g., locus coeruleus or prefrontal cortex) of anesthetized mice or rats. Alternatively, systemic administration may be used. Two-photon or confocal microscopy is performed through cranial windows to monitor noradrenergic microanatomy and synaptic activity in real time. Fluorescence intensity changes reflect norepinephrine dynamics.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties specific to FFN270 hydrochloride are not fully characterized as it is a research tracer rather than a therapeutic drug. The compound is designed for acute imaging applications and is expected to distribute to noradrenergic neurons via transporter-mediated uptake. It may be metabolized or cleared within hours of administration.
|
| Toxicity/Toxicokinetics |
Toxicity data for FFN270 hydrochloride are limited as it is a research tracer for in vitro and in vivo imaging. Standard safety assessment would include acute toxicity studies in rodents at imaging doses. No significant off-target toxicity has been reported in published literature at the concentrations used for fluorescence imaging (typically 1-10 microM in vitro, microg- to mg-range in vivo).
|
| References | |
| Additional Infomation |
FFN270 hydrochloride is a novel fluorescent tracer specifically designed for imaging the noradrenergic system. Its ability to serve as a ratiometric pH sensor expands its utility beyond transporter imaging to monitoring vesicular pH changes. As of current information, FFN270 is a research tool only and has not been developed for therapeutic applications or received regulatory approval.
|
| Molecular Formula |
C11H11CLFNO3
|
|---|---|
| Molecular Weight |
259.66
|
| Exact Mass |
259.041
|
| CAS # |
2341841-05-0
|
| PubChem CID |
138991779
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
17
|
| Complexity |
318
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
FC1C(=CC=C2C=C(CCN)C(=O)OC=12)O.Cl
|
| InChi Key |
DMAWKEXYKIZCQD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H10FNO3.ClH/c12-9-8(14)2-1-6-5-7(3-4-13)11(15)16-10(6)9;/h1-2,5,14H,3-4,13H2;1H
|
| Chemical Name |
3-(2-aminoethyl)-8-fluoro-7-hydroxychromen-2-one;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8512 mL | 19.2560 mL | 38.5119 mL | |
| 5 mM | 0.7702 mL | 3.8512 mL | 7.7024 mL | |
| 10 mM | 0.3851 mL | 1.9256 mL | 3.8512 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
